Treace Medical Concepts Inc

TMCI remains in a Stage 2 advancing phase with consistent higher highs and higher lows supported by rising EMAs, offering a medium-term bullish tradable side despite a broader secular downtrend. In the short term, price is pulling back into the 9/21 EMA zone without clear exhaustion or overbought signals. Following a speculative strategy, execution is deferred and aimed at shallow pullbacks into the dynamic support area.

• ↑Launched three new bunion systems, expecting volume growth in 2025
• ↑Active surgeon base achieved ~35% adoption of new systems
• ↓Q1 revenue fell 10% to $47.2 M; full-year guide set at −5% to flat